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Summary: The time-related frequency of elevated results for the mass concentrations of the MB isoenzyme
of creatine kinase and of troponin T were compared with that of creatine kinase and creatine kinase-MB
activity in patients with acute myocardial infarction. Patients (322; 175 with and 147 without myocardial
infarction) consecutively admitted for evaluation of possible acute myocardial infarction were investigated.
Reference limits for troponin T (0.1 g/l) and creatine kinase-MB mass concentration (5.0 g/l) were exceeded
frequently in patients with unstable angina pectoris (troponin T 43%, creatine kinase-MB mass concentration
24%) in contrast to patients with no acute ischaemic heart disease (both < 5%). Within 4 and between 4—8
hours after onset of chest pain, the frequency of elevated results for creatine kinase-MB mass concentration
and troponin T in patients with acute myocardial infarction was considerably higher (20 — 30%) than for
creatine kinase and creatine kinase-MB activity. Creatine kinase-MB mass concentration and troponin T both
allowed earlier diagnosis of acute myocardial infarction than creatine kinase and creatine kinase-MB activity,
but troponin T was not elevated before the creatine kinase-MB mass concentration.
Introduction
Early diagnosis of acute myocardial infarction is im-
portant for
(1) instigating and monitoring proper'therapy,
(2) preventing inappropriate usage of expensive cor-
onary care beds, and
(3) avoiding premature hospital discharge of patients
with myocardial infarction.
Diagnosis of acute myocardial infarction is based on
the characteristic clinical history of anginal chest dis-
comfort more than 30 minutes in duration, the evo-
lution of typical electrocardiographic changes and the
rise and fall of the activities of specific cardiac en-
zymes in blood. The positive predictive value of elec-
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trocardiographic abnormalities at admission has been
reported to be 72% (1). Serial electrocardiograms,
which are time-consuming, improved the positive pre-
dictive value, but nevertheless the electrocardiogram
was misleading in about 8% of all acute myocardial
infarctions and indeterminate in an additional 12%
(2). Therefore, measurement of specific cardiac en-
zymes and proteins play an important role in the early
and definitive diagnosis of acute myocardial infarc-
tion in a significant number of patients.
') Enzymes:
Alaiiine aminotransferase, EC 2.6.1.2,
Aspartate aminotransferase, EC 2.6.1.1,
Creatine kinase, EC 2.7.3.2,
Lactate dehydrogenase, EC 1.1.1.27
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Among the various biochemical approaches, deter-
mination of the enzyme activity of creatine kinase1)
and creatine kinase isoenzyme MB are generally used
for early diagnosis of acute myocardial infarction,
although the resulting diagnosis is not unequivocal
(3). The immunological determination of the mass
concentration of creatine kinase-MB represents a re-
cent advance towards greater specificity (4-8); unlike
the determination of the activities of creatine kinase
and its MB-isoenzyme, it is not prone to interference
from haemolysis (9, 10) or atypical and macromolec-
ular forms of creatine kinase (11 — 13). The immu-
nological determination of the cardiospecific troponin
T, a Mr 37000 polypeptide subunit of the cardiac
myofibrillar regulatory troponin complex, was also
recently proposed as a very sensitive and specific
marker for myocardial damage (14—18). It was sug-
gested (15) that the release from the damaged myo-
cardium led to a rise of troponin T in the serum,
which preceded the rise of creatine kinase and creatine
kinase-MB and remained elevated after myocardial
infarction for up to several weeks (18), in contrast to
the few days duration for the elevation of creatine
kinase and creatine kinase-MB. Troponin T therefore
seemed to be an attractive marker both for the early
and the late diagnosis of myocardial infarction.
In the present evaluation, we validated the reference
ranges for the assays under consideration, using re-
sults from patients admitted for evaluation of possible
myocardial infarction, but shown to be free from this
condition at the time. Furthermore, we studied the
time-related frequency of elevated results for the mass
concentration of creatine kinase-MB and troponin T
and compared it with that of the activity of creatine





The study population consisted of all consecutive patients ad-
mitted during a nine month period to the coronary care unit
of the "Medisch Centrum Leeuwarden" hospital in Leeuwar-
den, for evaluation of suspected myocardial infarction. Only
those patients were included for whom the time of onset of
chest pain was established with certainty and the time-period
between onset of chest pain and admission was < 12 hours.
The final diagnosis, according to the criteria of the World
Health Organization (19), was established by an independent
cardiologist (B. v. V.), without knowledge of the results of the
mass concentration of creatine kinase-MB and troponin T.
Patients considered to have muscle injury (cases of resuscitation
and/or defibrillation) were grouped separately, because muscle
trauma possibly could influence the release pattern of the car-
diac markers. On the other hand, patients who collapsed before
admission were included in the study although muscle injury
could not be excluded with certainty.
Patients' samples
Blood samples were taken at the time of admission to hospital
and during the first 24 hours in a fixed time schedule at 07.30,
14.30 and 21.30, which is routine in our hospital. The activities
of creatine kinase, lactate dehydrogenase1), aspartate
aminotransferase1) and alanine aminotransferase1) were deter-
mined as soon as possible, using the methods proposed by the
International Federation of Clinical Chemistry, and creatine
kinase-MB was assayed with an iminunoinhibition method (re-
agents from Boehringer Mannheim, Mannheim, Germany). For
the immunological determination of serum troponin T and the
mass concentration of creatine kinaserMB, samples were frozen
at — 20 °C until analysis.
Reference population for creatine kinase-MB mass concentration
and troponin T
Reference ranges were established using sera from apparently
healthy blood donors: 77 men and 45 women for the reference
range for the mass concentration of creatine kinase-MB; 63
men and 32 women for the concentration of troponin T. These
reference ranges were verified using the sera from patients
admitted for evaluation of acute myocardial infarction, but
shown to be free from this condition.
Diagnostic criteria
Classification of the patients
Patients were classified as acute myocardial infarction, unstable
angina pectoris, without acute ischaemic heart disease, arid as
other cardiac diseases. The final diagnosis of myocardial in-
farction was established if a patient had at least two of the
three following classic findings.
1) A clinical history of ischaemic chest discomfort of > 30 min
duration.
2) Typical changes in at least 2 leads to the electrocardiographic
recordings. If Q waves > 0.04 s appeared, or an R wave
increment gave an R/S ratio > 1 in leads VI and V2, it was
called Q wave infarction. If ST segment depression > 1 mm
occurred 0.08 s after the J point, or ST segment elevation
> 1 mm persisted for at least 24 hours, it was called non-Q
wave infarction.
3) Time-dependent changes of serum creatine kinase and cre-
atine kinase-MB activity, with an initial rise (with a peak
creatine kinase-MB activity exceeding twice the upper ref-
erence limit) and a subsequent fall.
Unstable angina pectoris was defined as typical anginal pain at
rest in combination with reversible or persistent electrocardio-
graphic changes, but without a peak value of the activity of
creatine kinase-MB exceeding twice the upper reference limit.
Patients were classified as without acute ischaemic heart disease,
if angina could be excluded by a definitive alternative source
of the chest pain, or in cases of an atypical history with a
negative stress electrocardiogram, myocardial scintigraphy or
coronary angiography.
Patients with other heart diseases were grouped separately,
together with a few patients for whom no final diagnosis could
be made.
Analytical methods
Catalytic activity of creatine kinase was measured at 30 °C with
a Hitachi 717 analyser by the rnethqd proposed by the Inter-
national Federation of Clinical Chemistry (10), using commer-
cial reagents (prod. Nos. 475742 and 475769) supplied by Boeh-
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ringer Mannheim. The upper reference limit for creatine kinase,
based on blood donors, was 130 U/l for men and 90 U/l for
women.
Catalytic activity of creatine kinase-MB was measured by im-
munoinhibition, using the appropriate antibody (Boehringer
Mannheim; prod. No. 418234) and the creatinc kinase assay
method, on the Hitachi 717 analyser. The upper reference limit
for the activity of creatine kinase-MB, based on blood donors,
was 15 U/l.
Cardiac troponin T in serum was measured with an enzyme-
linked immunosorbent assay (Boehringer Mannheim; prod. No.
1086987) developed by Kaius et al. (14, 16). This assay was
carried out in coated tubes, using the microprocessor-controlled
batch analyser ES-33 (Boehringer Mannheim). The method is
based on a single-step sandwich principle, with streptavidin-
coated test tubes as the solid phase and two monoclonal anti-
human cardiac troponin T antibodies. The biotinylated anti-
troponin T antibody binds completely to the streptavidin-
coaled test tube. This antibody binds troponin T from standards
or unknown samples. The peroxidase-labelled anti-troponin T
antibody is captured by the complex of biotinylated anti-tro-
ponin T and troponin T bound to the streptavidin-coated test
tube. The enzyme which remains in the test tubes after washing
corresponds to the amount of troponin T bound. This amount
is quantified at 405 nm after substrate conversion [di-ammo-
nium-2.2'-azino-bis(3-ethylbenzothiazoline-6-sulphonate)]. The
sensitivity limit of this assay was established at 0.10 μg/l (mean
absorbance of zero standard + 3 S. D.), which was in agreement
with Katuset al. (16).
Mass concentration ofcreatine kinase-MB was measured using
the microparticle capture enzyme immunoassay (22) from Ab-
bott Laboratories (Abbott Park, 1L; prod. No. 2207-20). In the
IMx creatine kinase-MB assay, a two-step protocol is used to
quantify creatine kinase-MB. In the initial incubation, creatine
kinase-MB in serum binds to anti-creatine kinase-MB micro-
particles. This microparticle/sanaple mixture is transferred to
the glass fibre matrix of the IMx disposable container. Anti-
creatine kinase-MM alkaline phosphatase conjugate is added,
followed by an additional incubation. The excess of conjugate
is washed from the matrix and the substrate (4-methyltimbel-
liferyl phosphate) is added. The amount of bound conjugate,
which is proportional to the amount of creatine kinase-MB in
the sample, is quantified from the rate at which the fluorescent
product is formed. The sensitivity of this assay was reported to
be 0.2 μ^Ι (20).
Statistical analysis
Differences in baseline characteristics (age, gender, clinical his-
tory and risk factors) between patients with and without acute
myocardial infarction were determined using a χ2 or Fisher's





































exact test for categorial, and Student's t test for continuous
variables. Comparison of the frequency of elevated results for
the different markers within patient groups was also performed
using Fisher's exact test.
For determining the clinical performance of the tested methods,
we calculated sensitivity (% of patients with myocardial infarc-
tion with a test result > the upper reference limit) and speci-
ficity (% of patients without myocardial infarction with a test
result <, the upper reference limit). Receiver operating char-
acteristic (ROC) curves were constructed to compare the dis-
criminative power of the tests. Areas under the curve and
differences between ROC curves were calculated according to
the method proposed by Hanley et al. (20, 21).
Results
Patient characteristics
Our study encompassed 322 patients. Acute myocar-
dial infarction was confirmed in 155 patients: 76 with
Q wave infarction and 79 with non-Q wave infarction.
Acute myocardial infarction was excluded in 127 pa-
tients: 69 were classified as unstable angina pectoris,
58 as lacking acute ischaemic heart disease (including
7 who collapsed before admission). Eleven patients
had other cardiac diseases, and for 4 patients no
definitive diagnosis could be made. Patients with other
cardiac diseases and patients with no definitive diag-
nosis were classified together as one group. The same
was done for patients (n = 25) who had been resus-
citated and/or defibrillated; myocardial infarction was
established in 20 of these, and other heart diseases
were diagnosed in the remaining 5. Table 1 summa-
rizes the number of patients in each patient group
admitted within 4 and 12 hours after onset of chest
pain, and the number of samples obtained within 4
and 24 hours after onset of chest pain, which were
analysed for all four markers. Baseline characteristics
(age, gender, risk factors and clinical history) of the
patient groups (details not shown here) were not
found to be significantly different between patients
with and without myocardial infarction, with the ex-
ception of a history of angina pectoris. The mean age
of the patient group without acute ischaemic heart
disease was also significantly lower (about eight years)
than for the other groups.
Reference range for mass concentration of
creatine kinase-MB
The reference range for the mass concentration of
creatine kinase-MB was estimated using 122 sera from
apparently healthy blood donors. The upper reference
limit (97.5th percentile) was determined according to
the proposed guidelines of the International Federa-
tion of Clinical Chemistry (23) and was found to be
5.0 μ§/1. This reference limit was validated using all
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31, 1993 / No. 11
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Creatine kinase-MB mass concentration
Fig. l. Distribution of the mass concentration of creatine ki-
nase-MB in 122 healthy blood donors (&), 58 patients
(127 samples) with no acute ischaemic heart disease (a)
and 69 patients (167 samples) with a final diagnosis of











Fig. 2. Distribution of the concentration of troponin T in 95
healthy blood donors (s), 58 patients (127 samples)
with no acute ischaernic heart disease (a) and 69 patients
(167 samples) with a final diagnosis of unstable angina
pectoris (i).
serum samples (n = 143) from the patients with no
acute ischaemic heart disease. In this patient group
95% of the results were < 5.0 μg/l. Using all serum
samples (n = 194) from patients with a final diagnosis
of unstable angina pectoris, however, only 77% of
the results were < 5.0 μg/l. In this patient group 95%
of the results were < 14 μg/l. The distribution of the
mass concentration of creatine kinase-MB in these
three groups is shown in figure 1.
consisted of patients admitted with the presumptive
diagnosis of acute mypcardial infarction, but with a
final diagnosis of no acute ischaemic heart disease. In
this patient group, there were only minor differences
between the frequencies of elevated results for all four
markers (fig. 3). In patients with unstable angina
pectoris, the frequency of elevated results for the
activity of creatine kinase and creatine kinase-MB did
not differ from that in patients with no acute is-
Reference range for t roponin Τ
The reference range for troponin T was estimated
using 95 sera from healthy blood donors. All but 2
sera from this reference population had a troponin Τ
concentration below the sensitivity limit. Therefore,
the upper reference limit for troponin T was estimated
at the sensitivity limit of 0.1 μg/l. Again the upper
reference limit was validated using all serum samples
(n = 141) from the patients with no acute ischaemic
heart disease. In this patient group 95% of the results
were < 0.1 μg/l. Using all serum samples (n = 204)
from patients with a final diagnosis of unstable angina
pectoris, however, only 60% of the results were < 0.1
μg/l. In this group 95% of the results were < 0.65
μg/l. The distribution of the concentration of troponin
T in these three groups is shown in figure 2.
Frequency of elevated results in patient
groups
The frequency of elevated results for the four cardiac
markers was determined for all serum samples taken
within 24 hours after onset of chest pain. Part of the
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Fig. 3. Frequency (Y) of results > the normalized concentra-
tion value oil the X-axis (X) for the activity of creatine
kinase (-T-Y-) and its MB isoenzyme
(^ H l· —) and creatine kinase-MB mass concentra-
tion (—#-#- ) and troponin T (—·-·-) in pa-
tients with no acute ischaemic heart disease (127 samples
from 58 patients). Concentrations of the four markers
on the X-axis are given as multiples of the upper ref-
erence limits. The used upper reference limits were:
creatine kinase: men 130 U^l; women 90 U/t, creatine
kinase-MB activity: 15 U/l/creatine kinase-MB mass
concentration: 5.0 μg/l> and troponin T: 0.1
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chaemic heart disease. However, the frequency of
elevated results for the mass concentration of creatine
kinase-MB and troponin T was considerably higher
in these patients (fig. 4). In patients with acute myo-
cardial infarction, the frequency of elevated results
for the four markers was related to the time interval
between onset of chest pain and the timing of the
sampling (figs. 5a —5d). An overview of the frequency
of elevated results in all patient groups is shown in
table 2. For creatine kinase-MB mass concentration
and troponin T, table 2 lists both the frequency of
elevated results using the upper reference limit, and
the frequency of elevated results compared with the
95% limit determined from the data obtained in pa-
tients with unstable angina pectoris.
Comparison of the diagnostic performance
The diagnostic performances of the four markers were
compared by ROC-curve analysis. As the release of
the markers after myocardial infarction depends on
the time elapsed since necrosis, we constructed time-
dependent ROC-curves (figs. 6a-6d).
The four markers were also evaluated for their ability
to detect patients with acute myocardial infarction
within 12 or 24 hours after the onset of chest pain
suggestive of acute myocardial infarction. Patients
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Fig. 4. Frequency (Y) of results > the normalized concentra-
tion value on the X-axis (X) for the activity of creatine
kinase ( — T — V — ) and its MB isoenzyme
(— Η h —) and creatine kinase-MB mass concentra-
tion (-#-#-) and troponin T (-· — ·-) in pa-
tients with unstable angina pectoris (167 samples from
69 patients): Concentrations of the four markers on the
X-axis are given as multiples of the upper reference
limits. The used upper reference limits were: creatine
kinase: men 130 U/I; women 90 U/l, creatine kinase-
MB activity: 15 U/l, creatine kinase-MB mass concen-
tration: 5.0 μg/lϊ and troponin T: 0.1 μg/l.
marker under consideration when at least one of the
time points gave an elevated result. Sensitivity and
specificity were calculated using the upper reference
limits for the four markers and the 95% limits esti-
mated for creatine kinase-MB mass concentration and
troponin T from the patients with unstable angina
pectoris (tab. 3).
Discussion
Reference ranges are usually determined by using
serum samples from healthy blood donors or labo-
ratory personnel, a rather young and healthy popu-
lation compared with the patients the test is meant
for. Therefore, we validated the reference range for
both the mass concentration of creatine kinase-MB
and troponin T by analysing samples from patients
with no acute ischaemic heart disease. For the mass
concentration of creatine kinase-MB, 95% of the re-
sults in this patient group were within the reference
range (> 5.0 μg/l). Seven out of 143 results were
above the upper reference limit, and all of these were
< 7.5 μg/l. The results for the mass concentration of
creatine kinase-MB obtained from healthy blood do-
1000 2 4 6 8 10 100
Normalized concentration
[multiples of upper reference limits]
Fig. 5. Frequency (Y) of results > the normalized concentra-
tion value on the X-axis (X) for the activity of creatine
kinase (— V — T —) and its MB isoenzyme-
(·— H 1—) and creatine kinase-MB mass concentra-
tion (—* — *—) and troponin T (—Η — π — ) in pa-
tients with acute myocardial infarction. The sample
results were divided according to the time delay since
onset of chest pain: samples obtained
(a) within 4 hours (n = 81),
(b) from 4-8 hours (n = 81),
(c) 8-12 hours (n = 73) and
(d) 12-16 hours (n = 72)
after onset of chest pain. Concentrations of the four
markers on the X-axis are given as multiples of the
upper reference limits. The used upper reference limits
were: creatine kinase: men 130 U/l; women 90 U/l,
creatine kinase-MB activity: 15 U/U creatine kinase-MB
mass concentration: 5.0 μ§/1, and troponin T: 0.1 ng/1.
Eur. J. Clin. Chem. din. Biochem. / Vol. 31,1993 / No. 11
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a: p < 0.05 and
b: p < 0.01: Significant difference of elevated results within patient groups according to Fishers exact test when compared with
total creatine kinase.
c: Muscle injury: patients who had been resuscitated and/or deflbrillated.
d: hours since onset of chest pain.
c: upper reference limit for creatine kinase.
Tab. 3. Frequency of patients in each patient group with at least one elevated result in the investigated time period for each
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b: Muscle injury: patients who had been resuscitated and/or defibrillated
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Fig. 6. ROC curves for the activity of creatine kinase
(— V — V —) and its MB isoenzyme (— H h —) and
creatine kinase-MB mass concentration ( — # — # — )
and troponin T ( — Β — π—) using all samples obtained
(a) within 4 hours,
(b) from 4—8 hours,
(c) 8 — 12 hours and
(d) 12-16 hours
after onset of chest pain.
Marker
Time since onset of chest pain
Area under the curve
(standard error)





0.59 (0.05) 0.76 (0.04)
0.63 (0.05) 0.82 (0.04)
0.76 (0.04) 0.88 (0.03)
0.67 (0.04) 0.86 (0.03)
Marker
Time since onset of chest pain
Area under the curve
(standard error)





0.97 (0.02) 0.95 (0.02)
0.97 (0.02) 0.96 (0.02)
0.99 (0.01) 0.98 (0.01)
0.94 (0.02) 0.94 (0.02)
nors agree with those obtained from patients with no
acute ischaemic heart disease. They also agreed with
the reference ranges found in other studies (6, 20, 24).
For the concentration of troponin T, 95% of the
results were below the upper reference limit of 0.1
μ§/1. Of the results (7 out of 141) above this limit,
only 1 exceeded 0.20 μg/l, the upper reference limit
suggested by the manufacturer. The results for tro-
ponin T in healthy blood donors also agree with those
obtained from patients with no acute ischaemic heart
disease. The upper reference limit found in this study
for troponin Τ is also in line with that (0.06 μg/l)
found by Gerhardt et al. (25), but is considerably
lower than that (0.5 μg/Ί) reported by Mair et al. (17).
The difference can be explained by the more sensitive
assay used in this study and by Gerhardt et al.
In patients with no acute ischaemic heart disease, the
frequency of elevated results for the activity of crea-
tine kinase (n = 19) and creatine kinase-MB (n = 14)
was slightly higher than for the mass concentration
of creatine kinase-MB and troponin T. Most of the
sera (n = 11), in which the activity of creatine kinase
exceeded the upper reference limit, displayed a normal
value for the ratio of the activity of creatine kinase-
MB to the activity of total creatine kinase (a ratio
< 6% excludes myocardial infarction). Four elevated
results were explained by the presence of a macro-
molecular creatine kinase. The remaining 4 samples
with an elevated activity of creatine kinase were hae-
molytic; since haemolysis is known to interfere in these
assays by the liberation of adenylate kinase from
erythrocytes (9), all elevated results for the activity of
creatine kinase are considered falsely elevated. The
elevated results for the activity of creatine kinase-MB
also were considered falsely elevated, since the sera in
question contained macromolecular creatine kinase (7
samples) or were subject to haemolysis (7 samples).
The assay for the mass concentration of creatine ki-
nase-MB and troponin T therefore led to a lower
frequency of falsely elevated results.
The ratio of the activity of creatine kinase-MB to the
total activity of creatine kinase is usually advocated
for the evaluation of myocardial damage in patients
with an elevated total creatine kinase activity. How-
ever, this ratio is worthless as a single indicator, be-
cause at low concentrations of total creatine kinase it
often gives rise to values > 6% (a ratio < 6% ex-
cludes myocardial infarction). This calculated indi-
cator was therefore not considered in this study.
The frequency of elevated results for troponin T and
the mass concentration of creatine kinase-MB in pa-
tients with unstable angina pectoris was significantly
higher than the frequency for the activities of both
creatine kinase and creatine kinase-MB. Almost 25%
of the results for the mass concentration of creatine
kinase-MB were above the upper reference limit. The
upper limit (95th percentile) for the mass concentra-
tion of creatine kinase-MB found in samples from
patients with unstable angina pectoris was estimated
at 14 μυ/l, which was considerably higher than the
upper reference limit. For troponin T, about 40% of
the results were above the upper reference limit, and
almost 25% were > 0.2 μ§/1, the upper reference limit
suggested by the manufacturer. The upper limit (95th
percentile) for troponin T found in samples from
patients with unstable angina pectoris was estimated
at 0.65 μ^Ι, which, like the mass concentration of
creatine kinase-MB, was considerably higher than the
upper reference limit. The occurrence of these slight
elevations for both the mass concentration of creatine
*Bur. j. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 11
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kinase-MB (26, 27) and troponin T (28) in patients
with unstable angina pectoris was described recently.
These slight elevations were correlated with a signif-
icantly higher risk for the development of acute my-
ocardial infarction and requiring revascularization.
Therefore, it is reasonable to suppose that minor
myocardial damage, which remained undetectable
with the less sensitive methods for creatine kinase and
creatine kinase-MB used so far, can release small
amounts of these proteins. The meaning of these slight
elevations of both the mass concentration of creatine
kinase-MB and troponin T (using these sensitive new
assays) in patients without myocardial infarction ac-
cording to the WHO criteria (using the insensitive
methods for measuring enzyme activity) however, re-
mains to be established. The frequency of elevated
results for both creatine kinase and creatine kinase-
MB activity in patients with unstable angina pectoris
did not differ from that of healthy blood donors.
The frequency of elevated results for the patients with
acute myocardial infarction was evaluated in different
time-windows, because the release of the markers is
time-dependent. Within 4 hours after the onset of
chest pain, suggestive of acute myocardial infarction,
< 20% of the patients displayed elevated values for
the activities of creatine kinase and creatine kinase-
MB. In about 50% of the patients, elevated results
were encountered for the mass concentrations of cre-
atine kinase-MB and troponin T. No significant dif-
ference was seen between the frequencies of elevated
results for the mass concentrations of creatine kinase-
MB and troponin T. Evaluation of the next 4 hour
period revealed at a higher percentage the same kind
of differences. Evaluation at more than 8 hours after
onset of chest pain showed no significant differences
between the frequency of elevated results for the ac-
tivities of creatine kinase and creatine kinase-MB and
the mass concentrations of creatine kinase-MB and
troponin T. Using the upper reference limits estimated
in samples from healthy blood donors and verified
with samples from patients with no acute ischaemic
heart disease, the sensitivity for both the mass con-
centration of creatine kinase-MB and troponin T was
considerably better in the first 12 hours after onset of
chest pain than the sensitivity for the activity of cre-
atine kinase and creatine kinase-MB (tab. 3). The
specificity, however, was worse. This was ascribed to
the rather high number of patients with a final diag-
nosis of unstable angina pectoris, who had elevated
results for the mass concentration of creatine kinase-
MB and/or troponin T. These patients with slight
elevations of creatine kinase-MB mass concentration
or troponin T are false-positive according to the
WHO criteria, but they possibly constitute a subgroup
of patients with myocardial infarction with an in-
creased risk of major cardiovascular disease as a con-
sequence of minor myocardial damage. Although the
best marker for early (within 12 hours after onset of
chest pain) diagnosis of acute myocardial infarction
(according to the WHO criteria) was the mass con-
centration of creatine kinase-MB according to the
ROC curve analysis, such a conclusion does not take
into account the importance of detecting minor my-
ocardial damage in patients not yet fulfilling the
WHO criteria for myocardial infarction. Such patients
probably carry an increased risk for major cardiovas-
cular disease, so that their detection might lead to a
more aggressive therapy (i.e. coronary angiography
followed by subsequent revascularization), which
might improve their prognosis.
By using the higher limits for the mass concentration
of creatine kinase-MB and troponin T (estimated in
patients with unstable pectoris), the specificity was
improved, with an accompanying loss of sensitivity.
Using these higher limits, the mass concentration of
creatine kinase-MB again was the best marker for the
early diagnosis of acute myocardial infarction, but
such a conclusion again does not take into account
the importance of detecting minor myocardial dam-
age.
In patients with myocardial infarction, Katus et al.
(15) presented data suggesting that the release of
troponin T precedes that of creatine kinase and cre-
atine kinase-MB determined by activity measurement.
Our results support their findings, but when we used
a sensitive assay for the determination of the mass
concentration of creatine kinase-MB, we found no
significant differences between the times of release of
troponin T and creatine kinase-MB. Our observation
that the mass concentration of creatine kinase-MB
rose before the activity of creatine kinase and creatine
kinase-MB has also been reported by others (6).
Therefore, we do not agree with Katus et al. that the
release of troponin T from the damaged myocardium
precedes that of creatine kinase-MB. Their observa-
tion was merely a consequence of the insensitive as-
says for the measurement of creatine kinase and cre-
atine kinase-MB activity.
In conclusion, we have shown (1) that troponin T and
the mass concentration of creatine kinase-MB display
the same release pattern after myocardial infarction,
(2) that for the early diagnosis of myocardial infarc-
tion according to the WHO criteria, the measurement
of the mass concentration of creatine kinase-MB per-
forms better (according to ROC curve analysis) in
comparison with troponin T rand the activity meas-
urements of creatine kinase and its MB-isoenzyme,
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 11
Bakker et al.: Acute myocardial infarction: Troponin T and crcatine kinases — mass vs activity 723
and (3) that in samples from patients with unstable
angina pectoris the mass concentrations of creatine
kinase-MB and troponin T are elevated in a consid-
erable number of the patients, which can be used to
identify a subgroup of patients without myocardial
infarction, who might benefit from a more aggressive
treatment. The measurement of the mass concentra-
tion of creatine kinase-MB is preferred for rapid and
early diagnosis of myocardial infarction, especially
when one considers that the measurement of troponin
T takes at least 90 min, whereas the mass concentra-
tion of creatine kinase-MB can be measured in less
than 10 min (29).
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